Revelation Biosciences, Inc. (REVB) Research

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Market snapshot

Symbol
REVB
Price
$0.98
Day change
-8.41%
Market cap
$3.8M
P/E ratio
-0.32x
52-week range
0.875-12.88
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Avenue Therapeutics, Inc. (ATXI)
  • Azitra, Inc. (AZTR)
  • GT Biopharma, Inc. (GTBP)
  • Indaptus Therapeutics, Inc. (INDP)
  • NKGen Biotech, Inc. Common Stock (NKGN)
  • Onconetix, Inc. (ONCO)
  • Psyence Biomedical Ltd. (PBM)
  • Salarius Pharmaceuticals, Inc. (SLRX)

Recent insider activity

  • Rolke James — F-InKind (10115 shares) on 2026-04-30
  • Zygmont Chester Stanley III — F-InKind (13285 shares) on 2026-04-30
  • ROPER JESS — F-InKind (1591 shares) on 2026-02-03
  • Chawla Lakhmir S — F-InKind (2261 shares) on 2026-02-03
  • CARVER JENNIFER — F-InKind (1661 shares) on 2026-02-03

Open Revelation Biosciences, Inc. (REVB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.